- Home
- SEER vs AGEN Comparison
SEER vs AGEN Comparison
Compare SEER & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEER
- AGEN
- Stock Information
- Founded
- SEER 2017
- AGEN 1994
- Country
- SEER United States
- AGEN United States
- Employees
- SEER N/A
- AGEN N/A
- Industry
- SEER Medicinal Chemicals and Botanical Products
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SEER Health Care
- AGEN Health Care
- Exchange
- SEER Nasdaq
- AGEN Nasdaq
- Market Cap
- SEER 105.0M
- AGEN 106.8M
- IPO Year
- SEER 2020
- AGEN 2000
- Fundamental
- Price
- SEER $1.77
- AGEN $6.05
- Analyst Decision
- SEER Hold
- AGEN Buy
- Analyst Count
- SEER 1
- AGEN 3
- Target Price
- SEER $3.00
- AGEN $10.00
- AVG Volume (30 Days)
- SEER 306.8K
- AGEN 368.6K
- Earning Date
- SEER 11-05-2024
- AGEN 11-05-2024
- Dividend Yield
- SEER N/A
- AGEN N/A
- EPS Growth
- SEER N/A
- AGEN N/A
- EPS
- SEER N/A
- AGEN N/A
- Revenue
- SEER $14,738,000.00
- AGEN $159,630,000.00
- Revenue This Year
- SEER N/A
- AGEN N/A
- Revenue Next Year
- SEER $43.19
- AGEN $0.04
- P/E Ratio
- SEER N/A
- AGEN N/A
- Revenue Growth
- SEER N/A
- AGEN 60.67
- 52 Week Low
- SEER $1.46
- AGEN $4.41
- 52 Week High
- SEER $2.48
- AGEN $25.40
- Technical
- Relative Strength Index (RSI)
- SEER 59.85
- AGEN 51.61
- Support Level
- SEER $1.65
- AGEN $4.75
- Resistance Level
- SEER $1.75
- AGEN $6.53
- Average True Range (ATR)
- SEER 0.06
- AGEN 0.38
- MACD
- SEER 0.02
- AGEN 0.27
- Stochastic Oscillator
- SEER 83.90
- AGEN 73.03
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).